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Rationale.	  Multiple	   lines	  of	  evidence	  suggest	  that	  the	  sex	  steroid	  hormone	  17-­‐β	  estradiol	  (E2)	   plays	   a	   protective	   role	   in	   schizophrenia.	   Systemic	   E2	   enhances	   prepulse	   inhibition	  (PPI)	  of	  the	  acoustic	  startle	  reflex,	  an	  operational	  measure	  of	  sensorimotor	  gating	  known	  to	  be	  impaired	  in	  schizophrenia	  and	  related	  disorders.	  However,	  the	  relative	  contribution	  of	  different	  estrogen-­‐receptor	  (ER)	  isoforms	  in	  these	  associations	  still	  awaits	  examination.	  
	  
Objectives.	   The	   present	   study	   explored	   the	   effects	   of	   ER-­‐α	   and	   ER-­‐β	   stimulation	   or	  blockade	  on	  PPI	  and	  their	  functional	  relevance	  in	  an	  amphetamine-­‐induced	  PPI	  deficiency	  model	  in	  male	  mice.	  	  
Methods.	  Prior	  to	  the	  assessment	  of	  PPI,	  C57BL/6N	  male	  mice	  were	  injected	  with	  the	  ER-­‐α	  agonist	   4,4’,4’’-­‐(4-­‐propyl-­‐[1H]-­‐pyrazole-­‐1,3,5-­‐triyl)trisphenol	   (PPT),	   the	   ER-­‐α	   antagonist	  1,3-­‐bis(4-­‐hydroxyphenyl)-­‐4-­‐methyl-­‐5-­‐[4-­‐(2-­‐piperidinylethoxy)phenol]-­‐1N-­‐pyrozole	  dihydrochloride	  (MPP),	  the	  ER-­‐β	  agonist	  2,3-­‐bis(4-­‐hydroxyphenyl)-­‐propionitrile	  (DPN),	  or	  the	   ER-­‐β	   antagonist	   4-­‐[2-­‐phenyl-­‐5,7-­‐bis(trifluoromethyl)	   pyrazolo[1,5-­‐a]pyrimidin-­‐3-­‐yl]phenol	  (PHTPP),	  with	  or	  without	  concomitant	  amphetamine	  treatment.	  	  
Results.	  Acute	   pharmacological	   stimulation	   and	   blockade	   of	   ER-­‐α,	   respectively,	   led	   to	   a	  dose-­‐dependent	   increase	   and	   decrease	   in	   basal	   PPI.	   In	   contrast,	   acute	   treatment	   with	  preferential	  ER-­‐β	  modulators	  spared	  PPI	  under	  basal	  conditions.	  Pretreatment	  with	  either	  ER-­‐α	   or	   ER-­‐β	   agonist	   was,	   however,	   effective	   in	   blocking	   amphetamine-­‐induced	   PPI	  disruption.	  	  	  	  	  
Conclusions.	  Our	   study	   demonstrates	   that	   activation	   of	   either	   ER	   isoform	   is	   capable	   of	  modulating	   dopamine-­‐dependent	   PPI	   levels.	   At	   the	   same	   time,	   our	   results	   suggest	   that	  endogenous	   ER-­‐α	   signaling	   may	   be	   more	   relevant	   than	   ER-­‐β	   in	   the	   regulation	   of	  sensorimotor	  gating	  under	  basal	  conditions.	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Introduction	  Schizophrenia	   is	   a	   chronic	   form	  of	  psychotic	   illness	   that	  affects	  approximately	  1%	  of	   the	  population	  worldwide	  (Tandon	  et	  al.	  2009).	  A	  large	  number	  of	  studies	  have	  demonstrated	  the	  existence	  of	  a	   clear	   sex	  dimorphism	   in	   the	  onset,	   severity	  and	  course	  of	   the	  disorder	  (Häfner	  et	  al.	  2003).	  For	  example,	  the	  onset	  of	  schizophrenic	  symptoms	  occurs	  on	  average	  1.5	  to	  4.5	  years	  later	  in	  women	  than	  in	  men	  (Angermeyer	  and	  Kühn,	  1988;	  Seeman,	  1997).	  There	  is	  also	  evidence	  to	  suggest	  that	  psychosis-­‐related	  symptoms	  vary	  across	  the	  estrous	  cycle	  in	  women,	  being	  most	  severe	  when	  estrogen	  levels	  are	  lowest	  and	  after	  menopause	  once	   17-­‐β	   estradiol	   (E2)	   levels	   are	   depleted	   (Angermeyer	   and	  Kühn,	   1988;	  Häfner	   et	   al.	  2003;	  Seeman,	  1997).	   Interestingly,	  schizophrenic	  male	  and	  female	  patients	  also	  typically	  exhibit	  lower	  estrogen	  levels	  as	  compared	  to	  healthy	  matched	  controls	  (Huber	  et	  al.	  2001,	  2005;	   Oades	   and	   Schepker,	   1994).	   Such	   epidemiological	   findings	   have	   been	   taken	   as	  evidence	   for	   a	   protective	   role	   of	   the	   sex	   hormone	   estrogen	   in	   the	   etiology	   and	  pathophysiology	   of	   schizophrenia	   (Häfner	   et	   al.	   2003),	   suggesting	   that	   estrogen-­‐related	  substances	   could	   represent	   relevant	   targets	   for	   the	   development	   of	   new	   medical	  treatments.	  	  	   Besides	   various	   other	   neuropsychological	   and	   cognitive	   deficits,	   patients	   with	  schizophrenia	   exhibit	   marked	   abnormalities	   in	   sensorimotor	   gating	   (Braff	   et	   al.	   2001).	  Prepulse	   inhibition	   (PPI)	   of	   the	   acoustic	   startle	   reflex	   is	   one	   of	   the	   best	   established	  translational	   paradigms	   that	   allows	   assessing	   sensorimotor	   gating	   functions	   both	   in	  humans	  and	  in	  rodent	  models	  (Koch	  and	  Schnitzler,	  1997;	  Light	  and	  Braff,	  1999).	  PPI	  refers	  to	  the	  reduction	  of	  startle	  reaction	  to	  a	  startle-­‐eliciting	  stimulus	  (pulse)	  when	  it	  is	  shortly	  preceded	  by	  a	  weak	  stimulus	  (prepulse)	  (Graham,	  1975;	  Hoffman	  and	  Searle,	  1965).	  It	  is	  an	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operational	  measure	  of	   sensorimotor	  gating,	   in	  which	  central	   gating	  mechanisms	  protect	  the	  processing	  of	  the	  information	  contained	  in	  the	  initial	  prepulse	  from	  distraction	  by	  the	  subsequent	  pulse	  stimulus	  (Swerdlow	  et	  al.	  2000).	  PPI	  thus	  reflects	  the	  ability	  to	  filter	  or	  gate	   intrusive	   sensory-­‐motor	   information.	   Disruption	   of	   such	   filtering	   mechanisms	   can	  result	   in	   central	   stimulus	   overload	   and	   associated	   dysfunctions	   in	   allocating	   the	   limited	  brain	  resources	   to	  only	   the	  most	   important	   stimuli	  encountered	   in	   the	  environment,	  and	  such	   abnormalities	   appear	   to	   be	   a	   core	   deficit	   in	   psychosis-­‐related	   disease	   (Braff	   et	   al.	  2001).	  	  	   Converging	  evidence	  from	  clinical	   investigations	   in	  humans	  and	  experimental	  studies	  in	   rodents	   indicate	   that	   E2	   administration	   can	   enhance	   PPI	   performance,	   when	  administered	  acutely	  (Van	  den	  Buuse	  and	  Eikelis,	  2001)	  or	  chronically	  (Gogos	  and	  Van	  den	  Buuse	   2004;	   Gogos	   et	   al.	   2006,	   2010,	   2012).	   Such	   investigations	   have,	   however,	   largely	  focused	   on	   females,	  whilst	   the	   putative	   benefits	   of	   estrogen-­‐receptor	   (ER)-­‐based	   ligands	  for	   treating	   schizophrenia-­‐relevant	   symptoms	   in	  males	   has	   attained	   less	   attention	   (Arad	  and	   Weiner,	   2010a,b;	   Kulkarni	   et	   al.	   2009,	   2011,	   2013).	   Yet,	   male	   mice	   with	   a	   genetic	  deletion	   of	   the	   estrogen-­‐synthetizing	   enzyme	   aromatase	   exhibit	   reduced	   PPI	   levels	   (Van	  den	  Buuse	  et	  al.	  2003),	  suggesting	  that	  the	  protective	  roles	  of	  E2	  could	  indeed	  extend	  to	  the	  male	  sex.	  It	  thus	  appears	  essential	  to	  determine	  whether	  estrogen-­‐related	  substances	  can	  modulate	   PPI	   levels	   in	   naïve	   male	   rodents	   because	   they	   could	   provide	   new	   targets	   for	  future	  therapeutic	  strategies	  for	  the	  male	  schizophrenia	  population	  (Kulkarni	  et	  al.	  2013).	  	   It	   also	   remains	   essentially	   unknown	   which	   ER	   subtypes	   are	   responsible	   for	   the	  beneficial	  effects	  of	  E2	  on	  PPI.	  The	  two	  main	  receptors	  for	  E2	  are	  ER-­‐α	  and	  ER-­‐β,	  both	  of	  which	   are	   expressed	   at	   the	   cellular	  membrane	   and	   in	   the	   cytosol	   (Heldring	   et	   al.	   2007).	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Animals	  	  	   Male	  C57BL/6N	  mice	  were	  obtained	  from	  Charles	  River	  (Sulzfeld,	  Germany)	  at	  the	  age	  of	  9-­‐10	  weeks.	  Testing	  began	  after	  2	  weeks	  of	  acclimatization	   to	   the	  new	  animal	  holding	  room	  that	  was	   temperature	  and	  humidity	  controlled	  (21±2	  1C,	  55±5%)	  with	  a	  12-­‐h	   light	  and	  12-­‐h	  dark	  cycle	  (lights	  off	  at	  0800	  h).	  All	  animals	  had	  ad	  libitum	  access	  to	  water	  and	  food	  (Kliba	  3436,	  Provimi	  Kliba	  NAFAG,	  Kaiseraugst,	  Switzerland)	  and	  were	  kept	  in	  groups	  of	   2–5	   animals	   per	   cage	   throughout	   all	   experimentation.	   Behavioral	   testing	   was	   always	  carried	  out	  during	  the	  dark	  phase	  of	  the	  diurnal	  cycle.	  	  	   All	  procedures	  had	  been	  previously	  approved	  by	  the	  Cantonal	  Veterinarian's	  Office	  of	  Zurich	  and	  are	  in	  agreement	  with	  the	  principles	  of	  laboratory	  animal	  care	  in	  the	  Guide	  for	  the	  Care	  and	  Use	  of	  Laboratory	  Animals	  (National	  Institutes	  of	  Health	  Publication	  No.	  86-­‐23,	  revised	  1985).	  All	  efforts	  were	  made	  to	  minimize	  the	  number	  of	  animals	  used	  and	  their	  suffering.	  	  
Prepulse	  inhibition	  of	  the	  acoustic	  startle	  reflex	  	   Sensorimotor	  gating	  was	  assessed	  using	   the	  paradigm	  of	  prepulse	   inhibition	   (PPI)	  of	  the	   acoustic	   startle	   reflex.	   The	   apparatus	   consisted	   of	   4	   startle	   chambers	   for	   mice	   (San	  Diego	  Instruments,	  San	  Diego,	  CA)	  as	  fully	  described	  elsewhere	  (Meyer	  et	  al.	  2005).	  In	  the	  demonstration	   of	   PPI	   of	   the	   acoustic	   startle	   reflex,	   the	   animals	   were	   presented	   with	   a	  series	  of	  discrete	   trials	   comprising	  a	  mixture	  of	  4	   trial	   types.	  These	   included	  pulse-­‐alone	  trials,	  prepulse-­‐plus–pulse	  trials,	  prepulse-­‐alone	  trials,	  and	  no-­‐stimulus	  trials	   in	  which	  no	  discrete	  stimulus	  other	  than	  the	  constant	  background	  noise	  was	  presented.	  The	  pulse	  and	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prepulse	   stimuli	   used	  were	   in	   the	   form	   of	   a	   sudden	   elevation	   in	   broadband	  white	   noise	  level	  (sustaining	  for	  40	  and	  20	  ms,	  respectively)	  from	  the	  background	  (65	  dBA),	  with	  a	  rise	  time	  of	  0.2–1.0	  ms.	  In	  all	  trials,	  3	  different	  intensities	  of	  pulse	  (100,	  110,	  and	  120	  dBA)	  and	  3	  intensities	  of	  prepulse	  (71,	  77,	  and	  83	  dBA,	  which	  corresponded	  to	  6,	  12	  and	  18	  dBA	  above	  background,	  respectively)	  were	  used.	  The	  stimulus-­‐onset	  asynchrony	  of	   the	  prepulse	  and	  pulse	  stimuli	  on	  all	  prepulse-­‐plus-­‐pulse	  trials	  was	  100	  ms	  (onset-­‐to-­‐onset).	  	   The	  protocol	  used	  for	   the	  PPI	   test	  was	  extensively	  validated	   in	  our	   laboratory	  before	  (e.g.,	  Labouesse	  et	  al.	  2013,	  Vuillermot	  et	  al.	  2010).	  A	  session	  began	  with	  the	  animals	  being	  placed	   into	   the	   Plexiglas	   enclosure.	   They	   were	   acclimatized	   to	   the	   apparatus	   for	   2	   min	  before	  the	   first	   trial	  began.	  The	   first	  6	   trials	  consisted	  of	  6	  startle-­‐alone	  trials;	  such	  trials	  served	  to	  habituate	  and	  stabilize	  the	  animals'	  startle	  response	  and	  were	  not	  included	  in	  the	  analysis.	   Subsequently,	   the	  animals	  were	  presented	  with	  10	  blocks	  of	  discrete	   test	   trials.	  Each	   block	   consisted	   of	   the	   following:	   3	   pulse-­‐alone	   trials	   (100,	   110,	   or	   120	   dBA),	   3	  prepulse-­‐alone	  trials	  (+6,	  +12,	  or	  +18	  dBA	  above	  background),	  9	  possible	  combinations	  of	  prepulse-­‐plus–pulse	  trials	  (3	  levels	  of	  pulse	  ×	  3	  levels	  of	  prepulse),	  and	  1	  no	  stimulus	  trial.	  The	  16	  discrete	  trials	  within	  each	  block	  were	  presented	  in	  a	  pseudorandom	  order,	  with	  a	  variable	   interval	   of	   15	   s	   on	   average	   (ranging	   from	   10	   to	   20	   s).	   For	   each	   of	   the	   3	   pulse	  intensities	   (100,	   110,	   or	   120	   dBA),	   PPI	   was	   indexed	   by	   percent	   inhibition	   of	   the	   startle	  response	  obtained	  in	  the	  pulse-­‐alone	  trials	  by	  the	  following	  expression:	  100%	  ×	  (1−[mean	  reactivity	   on	   prepulse-­‐plus-­‐pulse	   trials/mean	   reactivity	   on	   pulse-­‐alone	   trials]),	   for	   each	  animal,	   and	   at	   each	   of	   the	   3	   possible	   prepulse	   intensities	   (+6,	   +12,	   or	   +18	   dBA	   above	  background).	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Drug	  preparation	  and	  administration	  A	   first	   cohort	   of	  male	  mice	   (N	   =	   24)	  was	   used	   to	   study	   the	   effects	   of	   ER-­‐α	   selective	  modulators	  on	  basal	  PPI.	  All	  animals	  in	  this	  cohort	  first	  underwent	  an	  initial	  baseline	  PPI	  test	   without	   any	   drug	   treatment.	   This	   served	   to	   match	   the	   subsequent	   drug	   conditions	  according	   to	   their	   baseline	   PPI	   scores.	  One	  week	   after	   the	   baseline	   PPI	   test,	   the	   animals	  were	   treated	  with	   the	  ER-­‐α	   selective	   agonist	  PPT	   (Sigma-­‐Aldrich,	  Buchs,	   Switzerland)	   or	  corresponding	   vehicle	   (VEH)	   solution	   60	   min	   before	   PPI	   testing.	   While	   several	  experimental	   reports	   have	   documented	   the	   effective	   impact	   of	   E2	   on	   PPI	   after	   a	   30	  min	  pre-­‐treatment	   time	   (Van	   den	   Buuse	   and	   Eikelis,	   2001),	   other	   studies	   have	   provided	  evidence	  for	  the	  notion	  that	  striatal	  dopamine	  levels	  peak	  approximately	  60-­‐90	  min	  after	  systemic	   E2	   administration	   (Becker	   and	   Rudick,	   1999),	   thus	   providing	   experimental	  justification	   for	   the	  choice	  of	  a	  60-­‐min	  pretreatment	   time.	  This	   timepoint	  also	  allowed	  to	  target	   both	   (and	   perhaps	   equally	   important)	   genomic	   and	   non-­‐genomic	   signaling	  mechanisms	  of	  ER-­‐based	  drugs.	  PPT	  was	  dissolved	  in	  sterile	  NaCl	  containing	  10%	  ethanol	  and	  was	  administered	  at	  a	  dose	  of	  0	  (=VEH;	  N	  =	  8),	  1	  (N	  =	  8),	  or	  10	  mg/kg	  (N	  =	  8).	  	  After	   a	   drug	   wash-­‐out	   period	   of	   1	   week,	   the	   same	   animals	   were	   used	   to	   study	   the	  effects	  of	  the	  ER-­‐α	  selective	  antagonist	  MPP	  (Sigma-­‐Aldrich,	  Buchs,	  Switzerland)	  relative	  to	  VEH	  treatment,	  thereby	  counterbalancing	  the	  previous	  drug	  (PPT)	  history.	  To	  this	  end,	  we	  included	   the	   same	   amount	   of	   animals	   (one	   third)	   from	   each	   previous	   drug	   treatments	  (namely	  VEH,	  PPT-­‐1	  and	  PPT-­‐10)	  into	  each	  of	  the	  newly	  formed	  groups	  (namely	  VEH,	  MPP-­‐20	   and	   MPP-­‐200),	   so	   as	   to	   control	   for	   possible	   carry-­‐over	   effects	   of	   previous	   drug	  exposures.	   MPP	   was	   dissolved	   in	   sterile	   NaCl	   containing	   10%	   ethanol	   and	   was	  administered	  at	  a	  dose	  of	  0	  (=VEH;	  N	  =	  8),	  20	  (N	  =	  8),	  or	  200	  µg/kg	  (N	  =	  8)	  60	  min	  before	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PPI.	  The	  doses	  of	  MPP	  were	  chosen	  based	  on	  previous	  studies	  (Bliedtner	  et	  al.	  2010;	  Lund	  et	  al.	  2005;	  Santollo	  and	  Eckel,	  2009;	  Santollo	  et	  al.	  2007).	  	  A	  second	  cohort	  of	  male	  mice	  (N	  =	  24)	  was	  used	  to	  investigate	  the	  effects	  of	  selective	  ER-­‐β	  modulators	  on	  basal	  PPI.	  Again,	  all	  animals	   in	  this	  cohort	  were	   first	  subjected	  to	  an	  initial	  baseline	  PPI	  test	  without	  any	  drug	  treatment	  in	  order	  to	  match	  the	  subsequent	  drug	  conditions	   according	   to	   their	   baseline	   PPI	   scores.	   One	   week	   after	   this	   baseline	   test,	   the	  animals	  were	  treated	  with	  the	  ER-­‐β	  selective	  agonist	  (DPN)	  (Tocris	  Bioscience,	  Bristol,	  UK)	  or	  corresponding	  VEH	  solution	  60	  min	  before	  PPI	  testing.	  DPN	  was	  dissolved	  in	  sterile	  NaCl	  containing	  40%	  ethanol	  and	  was	  administered	  at	  a	  dose	  of	  0	  (=VEH;	  N	  =	  8),	  1	  (N	  =	  8),	  or	  10	  mg/kg	  (N	  =	  8).	  Although	  we	  cannot	  entirely	  exclude	   the	  possibility	   that	   the	  40%	  ethanol	  vehicle	  solution	  (equivalent	  to	  a	  1.5g/kg	  ethanol	  dose)	  could	  functionally	  interact	  with	  DPN	  to	  modulate	  PPI	   or	   startle,	   similar	  doses	  of	   ethanol	   failed	   to	  modulate	  PPI	   and	   startle	   in	  other	  experimental	   investigations	  conducted	  in	  C57BL/6	  mice	  (Bowers	  et	  al.	  2005;	  Lewis	  and	  Gould,	  2003;	  Owens	  et	  al.	  2003),	   suggesting	   that	   the	  vehicle	   solution	  chosen	   for	   this	  particular	   study	   would	   not	   represent	   confounders	   for	   the	   detection	   of	   primary	  experimental	   readouts	   of	   interest.	   After	   a	   drug	   wash-­‐out	   period	   of	   1	   week,	   the	   same	  animals	   were	   used	   to	   study	   the	   effects	   of	   the	   ER-­‐β	   selective	   antagonist	   PHTPP	   (Tocris	  Bioscience,	  Bristol,	  UK)	  relative	  to	  VEH	  treatment,	   thereby	  counterbalancing	  the	  previous	  drug	  (DPN)	  history.	  PHTPP	  was	  dissolved	  in	  corn	  oil	  and	  was	  administered	  at	  a	  dose	  of	  0	  (=VEH;	  N	  =	  8),	  0.4	  (N	  =	  8),	  or	  4	  mg/kg	  (N	  =	  8)	  60	  min	  before	  PPI	  testing.	  	  Two	  additional	  cohorts	  of	  male	  mice	  (N	  =	  32	  each)	  were	  used	  to	  assess	  the	  capability	  of	  the	  selective	  ER-­‐α	  modulators	  (cohort	  3)	  or	  ER-­‐β	  modulators	  (cohort	  4)	  to	  modify	  AMPH-­‐induced	   PPI	   deficits.	   All	   animals	   in	   cohorts	   3	   and	   4	   were	   first	   subjected	   to	   an	   initial	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baseline	   PPI	   test	   without	   any	   drug	   treatment	   in	   order	   to	   match	   the	   subsequent	   drug	  conditions	  according	  to	  their	  baseline	  PPI	  scores.	  D-­‐amphetamine	  sulfate	  (=	  AMPH;	  Sigma-­‐Aldrich,	  Buchs,	   Switzerland)	  was	  dissolved	   in	   sterile	  NaCl	   (=	   SAL)	   and	  administered	  at	   a	  dose	  of	  4.0	  mg/kg	  10	  min	  prior	  to	  PPI	  testing	  based	  on	  previous	  mouse	  studies	  (Flood	  et	  al.	  2010).	  	  In	   cohort	  3,	   the	  animals	  were	  assigned	   to	  1	  of	   the	  4	  experimental	  groups	   (N	  =	  8	  per	  group):	  SAL/VEH,	  AMPH/VEH,	  AMPH/PPT	  or	  AMPH/MPP.	  PPT	  and	  MPP	  were	  dissolved	  in	  sterile	   NaCl	   containing	   10%	   ethanol	   (=	   VEH)	   as	   described	   above	   and	   administered	   at	   a	  dose	  of	   10	  mg/kg	   and	  200	  µg/kg,	   respectively,	   60	  min	  prior	   to	  PPI	   testing	  based	  on	   the	  preceding	  experiments.	  The	  animals	  in	  cohort	  4	  were	  assigned	  to	  1	  of	  the	  4	  experimental	  groups	  (N	  =	  8	  per	  group):	  SAL/VEH,	  AMPH/VEH,	  AMPH/DPN	  or	  AMPH/PHTPP.	  DPN	  was	  dissolved	  in	  sterile	  saline	  containing	  40%	  ethanol,	  and	  PHTPP	  was	  dissolved	  in	  corn	  oil	  as	  described	  above.	  Based	  on	  the	  preceding	  experiments,	  DPN	  and	  PHTPP	  were	  administered	  at	  a	  dose	  of	  10	  mg/kg	  and	  4	  mg/kg,	   respectively,	  60	  min	  prior	   to	  PPI	   testing.	  Half	  of	   the	  animals	  assigned	  to	  the	  VEH	  group	  in	  cohort	  4	  received	  saline	  containing	  40%	  ethanol	  to	  match	   the	  DPN	   condition,	   and	   the	   other	   half	   received	   oil	   to	  match	   the	  PHTPP	   condition.	  Preliminary	  results	  showed	  that	  %PPI	  levels	  did	  not	  differ	  between	  these	  two	  types	  of	  VEH	  conditions	  (data	  not	  shown).	  	  Our	  administration	  doses	  were	  chosen	  based	  on	  previously	  published	  research	  studies	  outlining	  the	  bioactive	  effects	  of	  ER-­‐selective	  ligands	  (PPT,	  MPP,	  PHTPP	  and	  DPN)	  and	  their	  relative	  equivalence	  to	  the	  effects	  of	  estradiol.	  The	  PPT	  and	  DPN	  doses	  were	  chosen	  based	  on	  previous	  studies	   in	  rats	  outlining	  their	  effects	  on	  uterine	  weight	  and	  sexual	  behaviors	  (Frasor	   et	   al.,	   2003,	   Harris	   et	   al.,	   2002;	   Lundholm	   et	   al.	   2008;	   Mazzucco	   et	   al.,	   2008),	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   In	   the	   experimental	   series	   testing	   the	   effects	   of	   MPP,	   PPT,	   PHTPP	   or	   DPN	   on	   basal	  PPI,	   %	   PPI	   was	   analyzed	   using	   a	   3	   ×	   3	   ×	   3	   (treatment	   ×	   prepulse	   level	   ×	   pulse	   level)	  parametric	  ANOVA;	  and	  reactivities	  to	  pulse-­‐alone	  and	  prepulse-­‐alone	  trials	  were	  analyzed	  using	  a	  3	  ×	  3	  (treatment	  ×	  pulse	  level)	  and	  3	  ×	  3	  (treatment	  ×	  prepulse	  level)	  parametric	  ANOVA,	   respectively.	   In	   experimental	   series	   testing	   the	   effects	   of	   selective	   ER-­‐α	  modulators	   (MPP	   and	   PPT)	   or	   ER-­‐β	  modulators	   (DPN	   or	   PHTPP)	   on	   AMPH-­‐induced	   PPI	  deficits,	  %	  PPI	  was	  analyzed	  using	  a	  4	  ×	  3	  ×	  3	   (treatment	  ×	  prepulse	   level	  ×	  pulse	   level)	  parametric	  ANOVA;	  and	  reactivities	  to	  pulse-­‐alone	  and	  prepulse-­‐alone	  trials	  were	  analyzed	  using	  a	  4	  ×	  3	  (treatment	  ×	  pulse	  level)	  and	  4	  ×	  3	  (treatment	  ×	  prepulse	  level)	  parametric	  ANOVA,	  respectively.	  These	  analyses	  were	  followed	  by	  Fisher's	  LSD	  post-­‐hoc	  comparisons	  whenever	   appropriate.	   Statistical	   significance	  was	   set	   at	  p	   <	   0.05.	   All	   statistical	   analyses	  were	  performed	  using	  the	  statistical	  software	  StatView	  (version	  5.0)	  implemented	  on	  a	  PC	  running	  the	  Windows	  XP	  operating	  system.	  
	  
Results	  
Acute	  ER-­‐α	  activation	  by	  systemic	  PPT	  administration	  enhances	  PPI	  	   First,	  we	  explored	   the	  consequences	  of	  acute	  ER-­‐α	  activation	  on	  sensorimotor	  gating	  by	  assessing	  the	  effects	  of	  systemic	  administration	  of	  the	  ER-­‐α	  selective	  agonist	  PPT	  on	  PPI	  in	  male	  mice.	  The	  analysis	  of	  %	  PPI	  revealed	  a	  significant	  overall	  difference	  in	  %	  PPI	  levels	  across	   the	  different	  pharmacological	   treatment	  groups	   (main	  effect	  of	   treatment:	  F(2,21)	  =	  3.61,	  p	  <	  0.05).	  Post-­‐hoc	  analyses	  revealed	  that	  the	  high	  dose	  of	  PPT	  (10	  mg/kg,	  s.c.)	  led	  to	  a	  significant	  (p	  <	  0.05)	  increase	  in	  PPI,	  whereas	  the	  low	  dose	  of	  PPT	  (1	  mg/kg)	  failed	  to	  do	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so.	  As	  summarized	  in	  Fig.	  1a,	  the	  mean	  PPI	  scores	  were	  ~20%	  higher	  in	  mice	  injected	  with	  10	  mg/kg	  PPT	  compared	  to	  VEH-­‐treated	  animals.	  The	  interaction	  between	  drug	  and	  pulse	  levels,	  and	  between	  drug	  and	  prepulse	  levels,	   failed	  to	  reach	  statistical	  significance	  in	  the	  analysis,	  suggesting	  that	  the	  PPI-­‐ameliorating	  effects	  of	  PPT	  largely	  emerged	  independently	  of	  the	  precise	  pulse	  stimuli	  used	  (Fig.	  1a).	  	  	  	   As	  expected,	  the	  reactivity	  to	  pulse-­‐alone	  trials	  increased	  with	  increasing	  pulse	  levels	  (main	  effect	  of	  pulse	  levels:	  F(2,42)	  =	  12.46,	  p	  <	  0.001)	  and	  this	  effect	  was	  similar	  in	  all	  three	  treatment	   groups	   (Fig.	   1b).	   PPT	   treatment	   did	   also	   not	   affect	   the	   reactivity	   to	   prepulse-­‐alone	  trials	  (data	  not	  shown).	  Together,	  these	  data	  suggest	  that	  the	  ER-­‐α	  selective	  agonist	  PPT	   induces	   a	   dose-­‐dependent	   enhancement	   of	   basal	   PPI	   in	   the	   absence	   of	   concomitant	  changes	  in	  pulse	  or	  prepulse	  reactivity.	  
	  
Acute	  ER-­‐α	  blockade	  by	  systemic	  MPP	  administration	  attenuates	  PPI	  	   Next,	  we	  explored	   the	  effects	  of	  acute	  ER-­‐α	  blockade	  on	  sensorimotor	  gating	   in	  male	  mice.	  To	  this	  end,	  we	  pretreated	  the	  animals	  with	  two	  distinct	  doses	  (20	  and	  200	  µg/kg)	  of	  the	   selective	   ER-­‐α	   antagonist	  MPP	   before	   the	   assessment	   of	   PPI.	   As	   depicted	   in	  Fig.	   2a,	  MPP	   treatment	   led	   to	   a	   dose-­‐dependent	   attenuation	  of	  %	  PPI:	  Whereas	   animals	   injected	  with	  VEH	  and	  the	   low	  dose	  of	  MPP	  displayed	  highly	  comparable	  PPI	   levels,	  pretreatment	  with	  the	  high	  dose	  of	  MPP	  reduced	  the	  mean	  %	  PPI	  scores	  by	  ~30%.	  Statistical	  support	  for	  these	   impressions	  was	  obtained	  by	   the	  presence	  of	  a	   significant	  main	  effect	  of	   treatment	  (F(2,21)	  =	  3.35,	  p	  <	  0.05),	  and	  by	  the	  subsequent	  post-­‐hoc	  analyses	  confirming	  a	  significant	  difference	   between	  mice	   injected	  with	   the	   high	   dose	   of	  MPP	   and	   VEH-­‐treated	  mice	   (p	   <	  0.05)	  or	  mice	   treated	  with	   the	   low	  dose	  of	  MPP	   (p	   <	  0.05).	  The	  PPI-­‐disrupting	   effects	   of	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MPP	   emerged	   independently	   of	   the	   precise	   pulse	   or	   prepulse	   stimuli	   used,	   and	   no	  significant	  interaction	  involving	  treatment	  and	  pulse,	  or	  treatment	  and	  prepulse,	  emerged	  in	  the	  analysis	  of	  %	  PPI.	  	  	  The	  analysis	  of	  pulse-­‐alone	  trials	  confirmed	  that	  the	  overall	  startle	  reactivity	  increased	  with	  increasing	  pulse	  levels,	  leading	  to	  a	  significant	  main	  effect	  of	  pulse	  (F(2,42)	  =	  118.52	  ,	  p	  <	  0.001).	   This	   effect	   did	   not	   interact	  with	   the	   pharmacological	   treatment	   (Fig.	   2b).	  MPP	  treatment	   did	   also	   not	   affect	   the	   reactivity	   to	   prepulse-­‐alone	   trials	   (data	   not	   shown).	  Together,	   these	   data	   indicate	   that	   the	   ER-­‐α	   selective	   antagonist	   MPP	   dose-­‐dependently	  attenuates	  basal	  PPI	  in	  the	  absence	  of	  concomitant	  changes	  in	  pulse	  or	  prepulse	  reactivity.	  
	  
Acute	  ER-­‐β	  activation	  fails	  to	  affect	  basal	  PPI	  but	  reduces	  startle	  reactivity	  Given	   that	   acute	   pharmacological	   ER-­‐α	   stimulation	   increased	   basal	   sensorimotor	  gating	   (see	   Fig.	   1),	   we	   were	   interested	   in	   exploring	   whether	   similar	   effects	   could	   be	  obtained	  by	  selective	  ER-­‐β	  activation.	  Therefore,	  we	  assessed	  PPI	  following	  acute	  systemic	  treatment	  with	  the	  ER-­‐β	  selective	  agonist	  DPN	  (1	  or	  10	  mg/kg)	  or	  VEH.	  We	  found	  that	  the	  mean	  %	  PPI	  scores	  were	  largely	  comparable	  between	  the	  3	  treatment	  groups,	  even	  though	  administration	   of	   the	   low	   dose	   of	   DPN	   (1	   mg/kg)	   seemed	   to	   induce	   a	   slight	   but	   non-­‐significant	  reduction	  in	  %	  PPI	  at	  the	  100	  dB-­‐pulse	  condition	  (Fig.	  3a).	  No	  main	  effects	  or	  interactions	   involving	   the	   between-­‐subjects	   factor	   of	   treatment	   attained	   statistical	  significance	  in	  the	  analyses	  of	  %	  PPI.	  On	   the	   other	   hand,	   DPN	   treatment	   led	   to	   a	   dose-­‐dependent	   decrease	   in	   startle	  reactivity,	  which	  was	  most	  noticeable	  at	  the	  120	  dB-­‐pulse	  condition	  (Fig.	  3b).	  The	  analysis	  of	  pulse-­‐alone	  reactivity	  revealed	  a	  significant	  main	  effect	  of	  pulse	  levels	  (F(2,42)	  =	  80.34	  ,	  p	  <	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0.001)	   and	   its	   interaction	   with	   treatment	   (F(4,42)	  =	   2.66,	   p	  <	   0.05).	   Subsequent	   post-­‐hoc	  comparisons	   confirmed	   that	   animals	   treated	   with	   the	   high	   dose	   of	   DPN	   (10	   mg/kg)	  displayed	  a	  significant	  reduction	  in	  startle	  reactivity	  at	  the	  120	  dB-­‐pulse	  condition	  relative	  to	  VEH	  controls	  (p	  <	  0.05)	  or	  to	  animals	  treated	  with	  the	  low	  (1	  mg/kg)	  dose	  of	  DPN	  (p	  <	  0.05).	   DPN	   administration	   did	   not	   affect	   the	   reactivity	   to	   prepulse-­‐alone	   trials	   (data	   not	  shown).	  Together,	   these	  data	   suggest	   that	   the	  ER-­‐β	  selective	  agonist	  DPN	  does	  not	  affect	  basal	   PPI	   at	   effective	   doses	   that	   reduce	   startle	   reactivity.	   This	   impression	   was	   further	  confirmed	  by	  complementary	  analyses	  in	  experimental	  subgroups	  (artificially)	  matched	  for	  their	  startle	  reactivity	  levels	  (an	  approach	  documented	  by	  Geyer	  and	  Swerdlow,	  2001)	  by	  which	  extreme	  responders	  from	  each	  of	  the	  experimental	  groups	  were	  excluded.	  We	  found	  that	   DPN	   treatment	   did	   not	   affect	   PPI	   levels,	   even	   when	   startle	   levels	   were	   equal	  (Supplementary	  Fig.	  1),	  thus	  convincingly	  allowing	  to	  disambiguate	  the	  effects	  of	  DPN	  on	  startle	  and	  PPI.	  	  
Acute	  ER-­‐β	  blockade	  fails	  to	  affect	  basal	  PPI	  and	  startle	  reactivity	  In	  keeping	  with	  the	  PPI-­‐disrupting	  effects	  of	  acute	  ER-­‐α	  blockade	  (see	  Fig.	  2),	  we	  went	  on	   to	   investigate	   whether	   comparable	   effects	   might	   emerge	   following	   acute	  pharmacological	   inhibition	  of	   	  ER-­‐β.	  To	   this	  end,	  we	  treated	  mice	  with	   the	  ER-­‐β	  selective	  antagonist	  PHTPP	  (0.4	  or	  4	  mg/kg)	  or	  VEH	  prior	  to	  the	  assessment	  of	  PPI.	  At	   the	  chosen	  doses,	  however,	  PHTPP	  did	  not	  affect	  %	  PPI	  (Fig.	  4a),	  nor	  did	  it	  change	  startle	  reactivity	  to	  pulse	  alone	  trials	  (Fig.	  4b)	  or	  prepulse-­‐alone	  reactivity	  (data	  not	  shown).	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AMPH-­‐induced	  PPI	  deficits	  are	  attenuated	  by	  acute	  treatment	  with	  the	  ER-­‐α	  selective	  
agonist	  PPT	  	   In	   a	   next	   series	   of	   experiments,	   we	   tested	   whether	   treatment	   with	   ER-­‐α	   selective	  modulators	  might	  also	  be	  effective	   in	  modifying	  PPI	   in	  an	  acute	  hyperdopaminergic	  state	  that	   was	   induced	   by	   systemic	   administration	   of	   the	   indirect	   dopamine	   receptor	   agonist	  AMPH	  (4	  mg/kg).	  As	  expected,	  AMPH	  treatment	   led	  to	  a	  robust	  (~	  30	  %)	  reduction	   in	  %	  PPI	  compared	  to	  SAL	  control	  treatment	  (Fig.	  5a).	  The	  PPI-­‐reducing	  effects	  of	  AMPH	  were	  similarly	   seen	   in	  animals	  pretreated	  with	   the	  ER-­‐α	  selective	  antagonist	  MPP	  (10	  mg/kg),	  but	   absent	   in	   mice	   that	   received	   the	   ER-­‐α	   selective	   agonist	   PPT	   (200	   µg/kg)	   (Fig.	   5a).	  These	   effects	   led	   to	   a	   significant	  main	   effect	   of	   treatment	   (F(3,28)	  =	   5.96,	  p	  <	   0.01)	   in	   the	  analysis	   of	   %	   PPI.	   Subsequent	   post-­‐hoc	   comparisons	   confirmed	   a	   significant	   difference	  between	   the	   SAL/VEH	   and	  AMPH/VEH	  groups	   (p	  <	  0.01),	   the	   SAL/VEH	   and	  AMPH/MPP	  groups	  (p	  <	  0.001),	  the	  AMPH/PPT	  and	  AMPH/VEH	  groups	  (p	  <	  0.01),	  and	  the	  AMPH/MPP	  and	  AMPH/PPT	  groups	  (p	  <	  0.05).	  	   Mice	   assigned	   to	   the	   AMPH/MPP	   group	   tended	   to	   exhibit	   lower	   levels	   of	   startle	  reactivity	  to	  pulse	  alone-­‐trials	  (Fig.	  5b),	  but	  this	  effect	  did	  not	  reach	  statistical	  significance.	  Similarly,	  AMPH,	  neither	  alone	  nor	  in	  combination	  with	  MPP	  or	  PPT,	  affected	  the	  reactivity	  to	  prepulse-­‐alone	   trials	   (data	  not	   shown).	  Together,	   these	  data	  show	  that	  AMPH-­‐induced	  PPI	   deficits	   are	   attenuated	   by	   acute	   treatment	   with	   the	   ER-­‐α	   selective	   agonist	   PPT	  independently	  of	  concomitant	  effects	  on	  pulse	  or	  prepulse	  reactivity.	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AMPH-­‐induced	   PPI	   deficits	   are	   attenuated	   by	   systemic	   treatment	   with	   the	   ER-­‐β	  
selective	  agonist	  DPN	  Even	  though	  acute	  pharmacological	  modulation	  of	  ER-­‐β	  by	  systemic	  DPN	  and	  PHTPP	  treatment	  exerted	  no	  noticeable	  effects	  on	  PPI	  under	  basal	  conditions	  (see	  Fig.	  3	  and	  Fig.	  
4),	   we	   went	   on	   to	   test	   whether	   these	   ER-­‐β	   ligands	   might	   modify	   PPI	   in	   a	  hyperdopaminergic	  state	   induced	  by	  systemic	  AMPH	  treatment.	   In	   line	  with	  our	  previous	  findings	  (Fig.	  5a),	  we	  found	  that	  AMPH	  administration	  led	  to	  a	  marked	  (~	  35	  %)	  reduction	  in	   %	   PPI	   (Fig.	   6a).	   The	   PPI-­‐disrupting	   effects	   of	   AMPH	   similarly	   emerged	   in	   animals	  pretreated	   with	   the	   ER-­‐β	   selective	   antagonist	   PHTPP	   (4	   mg/kg).	   On	   the	   other	   hand,	  pretreatment	   with	   the	   ER-­‐β	   selective	   agonist	   DPN	   (10	   mg/kg)	   mitigated	   the	   negative	  consequences	   of	   AMPH	   on	   PPI	   (Fig.	   6a).	   Statistical	   support	   for	   these	   impressions	   was	  obtained	   by	   the	   significant	  main	   effect	   of	   treatment	   (F(3,28)	  =	   7.14,	   p	  <	   0.01),	   and	   by	   the	  subsequent	  post-­‐hoc	  comparisons	  revealing	  a	  significant	  difference	  between	  the	  SAL/VEH	  and	  AMPH/VEH	  groups	  (p	  <	  0.001),	  the	  SAL/VEH	  and	  AMPH/PHTPP	  groups	  (p	  <	  0.01),	  the	  AMPH/DPN	   and	   AMPH/VEH	   groups	   (p	  <	   0.05),	   and	   the	   AMPH/DPN	   and	   AMPH/PHTPP	  groups	  (p	  <	  0.05).	  	   The	  reactivities	  to	  pulse	  alone-­‐trials	  were	  largely	  comparable	  among	  the	  4	  groups	  (Fig.	  
6b),	  and	  no	  main	  effect	  or	   interaction	   involving	   the	  between-­‐subjects	   factor	  of	   treatment	  attained	  statistical	  significance	  in	  the	  analysis	  of	  startle	  reactivity.	  Similarly,	  AMPH,	  neither	  alone	   nor	   in	   combination	   with	   DPN	   or	   PHTPP,	   affected	   the	   reactivity	   to	   prepulse-­‐alone	  trials	  (data	  not	  shown).	  Together,	   these	  data	   indicate	   that	   the	  AMPH-­‐induced	  PPI	  deficits	  can	  be	  blocked	  by	  acute	  pretreatment	  with	  the	  ER-­‐β	  selective	  agonist	  DPN	  in	  the	  absence	  of	  concomitant	  effects	  on	  pulse	  or	  prepulse	  reactivity.	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Discussion	  The	  present	  study	  is	  the	  first	  demonstration	  that	  isoform-­‐specific	  ER	  ligands	  can	  effectively	  modulate	   PPI	   of	   the	   acoustic	   startle	   reflex	   in	   mice.	   Specifically,	   we	   demonstrate	   that	  systemic	   administration	   of	   the	   ER-­‐α	   agonist	   PPT	   can	   enhance	   PPI	   both	   under	   basal	   and	  hyperdopaminergic	  conditions,	  suggesting	  that	  signaling	  at	  ER-­‐α	  has	  a	  substantial	   impact	  on	   the	  modulation	   of	   sensorimotor	   gating.	   This	   impression	   is	   further	   supported	   by	   our	  findings	  showing	  that	  pharmacological	  blockade	  of	  ER-­‐α	  signaling	  by	  acute	  MPP	  treatment	  attenuates	  PPI.	   It	   thus	  appears	  that	  endogenous	  ER-­‐α	  signaling	  has	  a	  bidirectional	  role	   in	  the	  regulation	  of	  PPI,	  so	  that	  stimulation	  and	  attenuation	  of	  ER-­‐α	  signaling	  is	  linked	  to	  an	  enhancement	   and	   disruption	   of	   sensorimotor	   gating,	   respectively.	   Notably,	   such	  bidirectional	  effects	  are	  not	  unique	  to	  ER-­‐α	  signaling	  but	  have	  been	  described	  for	  various	  other	  neurotransmitter	  systems.	  Perhaps	  the	  best	  illustration	  in	  this	  context	  is	  the	  central	  dopamine	   system:	   It	   is	   well	   known	   that	  manipulations	   leading	   to	   enhanced	   presynaptic	  dopamine	  release	  and/or	  dopamine	  receptor	  stimulation	  (especially	  in	  striatal	  structures)	  impair	   PPI,	   whereas	   blockade	   of	   dopamine	   receptor	   signaling	   potentiates	   PPI	   and/or	  restores	  PPI	  deficits	  associated	  with	  hyperdopaminergic	  states	   (Swerdlow	  et	  al.	  2000).	   It	  should	  also	  be	  pointed	  out	  that	  the	  PPI-­‐modulating	  effects	  of	  ER-­‐α	  selective	  ligands	  likely	  represent	  genuine	  effects	  on	  central	  gating	  mechanisms.	  Indeed,	  they	  were	  not	  associated	  with	  concomitant	  changes	   in	  startle	  or	  prepulse	  reactivity,	  which	   in	   turn	  may	  complicate	  the	  interpretation	  of	  gating	  effects	  (Csomor	  et	  al.	  2008;	  Yee	  et	  al.	  2005).	  Our	  results	  further	  suggest	  the	  existence	  of	  a	  more	  functionally	  restricted	  role	  for	  ER-­‐β	  signaling	  in	  the	  modulation	  of	  PPI.	  Whereas	  selective	  ligands	  for	  the	  ER-­‐β	  receptor	  did	  not	  alter	  PPI	  scores	  under	  basal	  conditions,	  ER-­‐β	  activation	  efficiently	  enhanced	  PPI	  when	  the	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animals	  were	   shifted	   towards	   a	  hyperdopaminergic	   condition	  by	   acute	   administration	  of	  AMPH.	   One	   limitation	   of	   the	   present	   study	   is	   that	   the	   effects	   of	   ER-­‐α	   or	   ER-­‐β	   selective	  ligands	  were	  studied	  using	  two	  doses	  for	  each	  compound	  only.	  Hence,	  we	  cannot	  rule	  out	  the	  possibility	  that	  treatment	  with	  higher	  doses	  of	  ER-­‐β	  selective	  modulators	  may	  still	  be	  effective	   in	   modulating	   PPI	   under	   basal	   conditions.	   Importantly,	   although	   the	   ER-­‐β	  selective	   antagonist	   PHTPP	   was	   shown	   to	   effectively	   modulate	   behavioral	   functions	   by	  other	  laboratories	  when	  administered	  centrally	  (Dillon	  et	  al.	  2013;	  Saleh	  et	  al.	  2013),	  it	  did	  not	   exhibit	   biological	   activity	   in	   any	   of	   the	   experimental	   investigations	   described	   herein	  (peripheral	  administration)	  so	  that	  it	   is	  not	  feasible	  to	  fully	  conclude	  as	  to	  the	  absence	  of	  effects	  of	  PHTPP	  on	  PPI	  or	  startle.	  Indeed,	  one	  possible	  interpretation	  of	  our	  findings	  is	  that	  PHTTP	   does	   not	   affect	   PPI	   or	   startle	   because	   of	   a	   reduced	   bioactivity	   level	  within	   brain	  circuits	   involved	   in	   sensorimotor	   gating	   and	   future	   studies	   are	   thus	   required	   to	   address	  this	  possibility.	  	  On	   the	  other	  hand,	   it	  needs	   to	  be	  pointed	  out	   that	   treatment	  with	   the	  ER-­‐β	  selective	  agonist	   DPN	   was	   found	   to	   significantly	   reduce	   startle	   reactivity	   under	   basal	   conditions	  whilst	  leaving	  PPI	  unaffected.	  This	  dissociation	  may	  be	  indicative	  of	  the	  possibility	  that	  ER-­‐β	   signaling,	   at	   least	   under	   basal	   conditions,	   could	   be	   functionally	   more	   relevant	   for	   the	  regulation	   of	   the	   startle	   reflex	   per	   se	   as	   for	   the	   modulation	   of	   the	   gating	   mechanism	  underlying	   PPI	   (Koch	   and	   Schnitzler,	   1997).	   Further	   evidence	   for	   this	   experimental	  dissociation	  between	  startle	  and	  PPI	  arises	  from	  complementary	  analyses	  in	  experimental	  subgroups	   matched	   for	   their	   startle	   reactivity	   levels	   (as	   documented	   by	   Geyer	   and	  Swerdlow,	   2001).	   Using	   such	   approach,	  we	   readily	   demonstrate	   that	  DPN,	   under	   similar	  (matched)	   startle	   conditions,	   does	   not	   affect	   PPI	   levels	   (Supplementary	   Fig.	   1),	   thus	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suggesting	   that	   the	   effects	   of	   DPN	   on	   startle	   are	   likely	   not	   masking	   any	   of	   its	   possible	  effects	   on	   PPI.	   Even	   though	   this	   hypothesis	  warrants	   further	   investigations,	   it	   would	   be	  consistent	  with	  the	  proposal	  that	  the	  startle	  response	  and	  PPI	  represent	  two	  independent	  and	  somewhat	  dissociable	  processes	  (Blumenthal	  et	  al.	  2004;	  Ison	  et	  al.	  1997).	  Another	  possible	  explanation	  for	  the	  ineffectiveness	  of	  the	  ER-­‐β	  selective	  agonist	  DPN	  to	  enhance	  PPI	  under	  basal	  conditions	  may	  be	  related	  to	  the	  fact	  that	  the	  second	  cohort	  of	  animals	  (i.e.,	  those	  that	  were	  used	  to	  study	  ER-­‐β	  selective	  modulators)	  generally	  displayed	  high	  PPI	  scores,	  even	  after	  VEH	  treatment.	  Indeed,	  whereas	  the	  mean	  %	  PPI	  scores	  in	  VEH-­‐treated	  animals	  from	  cohort	  1	  ranged	  from	  50	  to	  60%,	  VEH-­‐treated	  animals	  from	  cohort	  2	  displayed	  %	   PPI	   scores	   between	   70	   to	   80%.	   Given	   this,	   the	   ineffectiveness	   of	   the	   ER-­‐β	  selective	  agonist	  DPN	   to	   increase	  basal	  PPI	  may	  be	   related	   to	  ceiling	  effects,	   that	   is,	   they	  could	   have	   been	   masked	   by	   high	   PPI	   scores	   in	   VEH-­‐treated	   animals.	   We	   have	   no	  parsimonious	  explanation	  for	  the	  apparent	  differences	  between	  the	  baseline	  PPI	  scores	  of	  cohort	  1	  and	  2.	  It	  should	  be	  noted,	  however,	  that	  individual	  differences	  in	  baseline	  PPI	  are	  not	  uncommon,	  and	  they	  do	  exist	  even	  within	  one	  particular	  mouse	  strain	  such	  as	  C57BL/6	  (see	  e.g.,	  Yee	  et	  al.	  2005).	  	  Even	   though	   the	   effectiveness	   of	   the	   ER-­‐α	   and	   ER-­‐β	   selective	   agonists	   differed	  with	  respect	  to	  the	  modulation	  of	  PPI	  under	  basal	  conditions,	  they	  were	  remarkably	  similar	   in	  their	  capacity	  to	  enhance	  PPI	  under	  hyperdopaminergic	  conditions.	  These	  findings	  readily	  emphasize	  a	  putative	  role	  of	  dopamine-­‐dependent	  mechanisms	  in	  the	  behavioral	  actions	  of	  ER-­‐α	   and	   ER-­‐β	   selective	   agonists.	   In	   support	   of	   this	   notion,	   E2	   is	   known	   to	   affect	  dopaminergic	   neurocircuits	   (Sánchez	   et	   al.	   2010),	   and	   it	   has	   been	   proposed	   that	   such	  effects	   readily	   contribute	   to	   the	  modulatory	   effects	   of	   E2	   on	   sensorimotor	   gating	   in	   the	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form	  of	  PPI	  (Gogos	  et	  al.	  2010,	  2012).	  Moreover,	  ER-­‐α	  and	  ER-­‐β	  are	  both	  expressed	  in	  some	  of	   the	   most	   important	   brain	   areas	   involved	   in	   the	   PPI	   circuitry,	   including	   the	   (ventral)	  striatum	   and	   midbrain	   dopaminergic	   nuclei	   (Kuppers	   and	   Beyer,	   1999;	   Laflamme	   et	   al.	  1998;	   Shughrue	  et	   al.	   1997;	  Toran-­‐Allerand,	  2004).	  Previous	   studies	  have	   further	   shown	  that	  E2	  treatment,	  can	  recruit	  ER-­‐α	  and	  ER-­‐β	  to	  efficiently	  modulate	  striatal	  dopaminergic	  signaling.	   For	   example,	   acute	   E2	   rapidly	  modifies	   dopamine	   release	   in	   the	   striatum,	   and	  these	  effects	  were	  shown	  to	  depend	  on	  both	  ER-­‐α	  and	  ER-­‐β	  subtypes,	  supporting	  the	  idea	  that	   these	   ERs	   exhibit	   functional	   activity	   in	   the	   striatum	   (likely)	   via	   recruitment	   of	   non-­‐genomic	   mechanisms	   (Bazzett	   and	   Becker,	   1994;	   Xiao	   et	   al.	   2003).	   Two-­‐week	   chronic	  administration	  of	  ER-­‐α	  and	  ER-­‐β	  selective	  ligands,	  that	  mostly	  involve	  genomic	  activity	  of	  ERs,	   similarly	   implicated	   dopaminergic	   signaling	   pathways	   (Le	   Saux	   et	   al.	   2006).	   Under	  such	  conditions,	  to	  target	  both	  (and	  perhaps	  equally	  important)	  genomic	  and	  non-­‐genomic	  signaling	  mechanisms,	  our	  series	  of	  investigations	  thus	  comprised	  of	  a	  treatment	  regimen	  whereby	   ER	   drugs	   were	   administered	   1	   hour	   prior	   to	   behavioral	   testing,	   in	   a	   test	   that	  lasted	  45	  min	  (Lösel	  and	  Wehling,	  2003).	  A	   number	   of	   distinct	   (but	   not	   mutually	   exclusive)	   processes	   have	   been	   proposed	  whereby	   ER	   signaling	   can	   modulate	   dopaminergic	   activity.	   One	   prevailing	   hypothesis	  suggests	   that	   activation	   of	   ERs	   located	   on	   presynaptic	   DA	   terminals	   or	   post-­‐synaptic	  dopaminoceptive	   neurons	   could	   modulate	   dopamine	   release	   (Madularu	   et	   al.	   2014),	  dopamine	   transporter	   (DAT)	   and	   D2	   receptors	   (D2R)	   activity	   and	   affinity	   (Bazzett	   and	  Becker,	  1994;	  Cyr	  et	  al.	  2002;	  Lévesque	  and	  Di	  Paolo,	  1988;	  Morissette	  et	  al.	  1990).	  Such	  effects	  have	  been	  repeatedly	  shown	  to	  emerge	  in	  the	  absence	  of	  gene	  expression	  changes	  (Di	  Paolo,	  1994).	  For	  example,	  an	  elegant	  study	  by	  Chavez	  and	  colleagues	  revealed	  that	  an	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E2	  administration	  regimen	  known	  to	  enhance	  PPI	  (Gogos	  et	  al.	  2006)	  leads	  to	  reductions	  in	  dopamine	   D2	   receptor	   density	   in	   the	   nucleus	   accumbens	   of	   OVX	   rats,	   and	   causes	   an	  increase	   in	   DAT	   density	   (Chavez	   et	   al.	   2010).	  Whether	   similar	  mechanisms	  may	   also	   be	  operative	  following	  administration	  of	  ER-­‐α	  and	  ER-­‐β	  selective	  agonists,	  and	  whether	  these	  may	   explain	   the	   PPI-­‐improving	   effects	   of	   these	   compounds	   under	   hyperdopaminergic	  conditions,	  warrants	  further	  investigation.	  Although	   the	   involvement	   of	   dopaminergic	  mechanisms	   appears	   compelling,	   various	  other	  neurochemical	  mechanisms	  may	  also	  be	  involved	  in	  the	  PPI-­‐modifying	  effects	  of	  ER	  ligands.	   Indeed,	   E2	   was	   previously	   shown	   to	   blunt	   the	   deleterious	   effects	   of	   the	   NMDA	  antagonist	  MK-­‐801	   on	   PPI	   (Gogos	   et	   al.	   2012;	   Van	   den	  Buuse	   and	   Eikelis,	   2001)	   and	   on	  selective	   attention	   learning	   (Arad	   and	   Weiner,	   2010b).	   Several	   studies	   have	   further	  implicated	  5-­‐HT1	  and	  5-­‐HT2A	   serotonergic	   receptors	   in	   the	  behavioral	   effects	   of	  E2	   and	  related	  ligands	  (Cyr	  et	  al.	  2002;	  Fink	  et	  al.	  1998;	  Gogos	  et	  al.	  2012;	  Weiner	  and	  Arad,	  2009).	  These	   mechanisms	   may	   be	   particularly	   important	   in	   mediating	   the	   effects	   of	   the	   ER-­‐α	  selective	   agonist	   PPT	   on	  PPI	   given	   that	   this	   drug	  was	   shown	   to	   enhance	  PPI	   levels	   both	  under	  basal	  and	  hyperdopaminergic	  conditions.	  Indeed,	  one	  limitation	  of	  our	  study	  is	  that	  we	  did	  not	  include	  a	  SAL/PPT	  group	  in	  the	  AMPH	  experimental	  investigations	  so	  that	  it	  is	  not	   feasible	   to	   conclude	   whether	   PPT	   functionally	   rescues	   the	   AMPH-­‐effects	   on	   PPI,	   or	  rather	  whether	  PPT	  enhances	  PPI	  in	  an	  additive	  fashion	  via	  other	  (unrelated)	  mechanisms.	  Additional	   studies	   are	   thus	   clearly	   warranted	   to	   further	   delineate	   the	   precise	  neurochemical	   processes	   underlying	   the	   PPI-­‐modifying	   effects	   of	   ER	   isoform-­‐specific	  ligands.	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Whatever	   precise	   mechanisms	   involved,	   our	   findings	   clearly	   add	   to	   the	   growing	  literature	   suggesting	   that	   estrogen-­‐related	   substances	  may	  have	   therapeutic	   value	   in	   the	  treatment	  of	  psychosis-­‐related	  behavioral	  and	  cognitive	  deficits	  (Arad	  and	  Weiner,	  2010b;	  Frye	  et	  al.	  2007;	  Gogos	  et	  al.	  2006,	  2010,	  2012;	  Uban	  et	  al.	  2012;	  Van	  den	  Buuse	  and	  Eikelis,	  2001).	   For	   instance	   the	   ER-­‐α	   agonist	   PPT	   seems	   to	   represent	   a	   remarkably	   potent	  pharmacological	   compound	   that	   could	   possibly	   modulate	   PPI	   in	   populations	   of	   patients	  with	   sensorimotor	   gating	   pathologies	   of	   distinct	   etiology/pathophysiology	   given	   its	  significant	   effects	   on	   PPI	   both	   in	   normo-­‐dopaminergic	   and	   hyper-­‐dopaminergic	   states.	  Notably,	   since	  our	   study	  was	   conducted	   in	  male	  mice,	   our	   findings	   support	   the	   idea	   that	  such	  estrogen-­‐based	  interventions	  may	  not	  only	  be	  beneficial	  for	  female	  subjects	  suffering	  from	  psychosis-­‐related	  disturbances,	  but	  could	  be	  readily	  extended	  to	  the	  pharmacological	  treatment	   of	   the	   male	   schizophrenic	   population.	   Thus	   far,	   only	   a	   small	   number	   of	   pilot	  studies	  have	   investigated	  potential	  benefits	  of	  estrogen	  as	  an	  adjunctive	   therapy	   for	  men	  with	  schizophrenia	  (Kulkarni	  et	  al.	  2009,	  2011,	  2013).	  Unfortunately,	   the	  risk	  of	   inducing	  hormone-­‐dependent	   cancers,	   and	   the	   possibility	   that	   such	   therapy	  may	   have	   feminizing	  effects	   in	   the	   male	   population,	   has	   limited	   the	   applicability	   of	   an	   adjunctive	   estrogen	  therapy	  in	  male	  schizophrenic	  patients	  (Cyr	  et	  al.	  2002;	  Kulkarni	  et	  al.	  2009).	  The	  use	  of	  ER	  selective	   ligands	   may	   be	   less	   prone	   to	   such	   side	   effects	   as	   they	   would	   allow	   reducing	  administration	   doses,	   thus	   limiting	   the	   emergence	   of	   estrogen-­‐related	   peripheral	   side-­‐effects.	   An	   interesting	   candidate	   for	   these	   purposes	   would	   be	   the	   ER-­‐β	   agonist	   DPN	  because	   it	   enhanced	   PPI	   levels	   under	   hyperdopaminergic	   conditions	   and	   is	   known	   to	  mostly	  spare	  peripheral	  functions	  (Bliedtner	  et	  al.	  2010;	  Le	  Saux	  et	  al.	  2006;).	  Against	  these	  backgrounds,	   our	   study	   may	   thus	   encourage	   additional	   investigations	   aiming	   at	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Supplementary	  Figure	  1.	  Effects	  of	  the	  ER-­‐β	  selective	  agonist	  DPN	  on	  PPI	  after	  prior	  matching	  of	  pulse-­‐induced	  startle	  reactivity	  levels	  among	  all	  three	  experimental	  groups.	  Mice	  were	  injected	  with	  vehicle	  (VEH;	  =	  0	  mg/kg)	  or	  DPN	  at	  a	  low	  dose	  (1	  mg/kg	  body	  weight)	  or	  high	  dose	   (10	  mg/kg	  body	  weight)	  60	  min	  before	  PPI	   testing.	  (a)	  The	   line	  plot	  shows	  percent	  prepulse	  inhibition	  (%	  PPI)	  as	  a	  function	  of	  the	  three	  distinct	  pulse	  levels	   (P-­‐100,	   P-­‐110,	   and	   P-­‐120,	   which	   correspond	   to	   100,	   110	   and	   120	   dBA)	   and	  prepulse	   levels	   (+6,	   +12	  and	  +18	  dBA	   above	  background	  of	  65	  dBA);	   and	   the	  bar	  plot	  depicts	  the	  mean	  %	  PPI	  across	  all	  prepulse	  and	  pulse	  stimuli	  used.	  (b)	  The	  graph	  shows	  startle	   reactivity	   (in	   arbitrary	   units,	   AU)	   to	   pulse-­‐alone	   trials	   for	   the	   three	   different	  pulse	   levels.	   	   N	   =	   5	   per	   group	   (after	   excluding	   the	   3	   extreme	   responders	   in	   each	  experimental	  group	  for	  the	  purpose	  of	  matching	  pulse-­‐induced	  startle	  reactivity	  levels);	  all	  values	  are	  means±SEM.	  
